EOCRCPred: An Artificial Intelligence–Based Prognostic Model Integrating Serum CEA and Clinical Factors for Early‐Onset Colorectal Cancer
International Journal of Clinical Practice · 2026-01 · 2026 (1)
DOI: 10.1155/ijcp/9512983 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Practice, online erschienen am 04.11.2026. Verfasst von Guangsheng Wan und 8 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission, Shanghai University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Purpose
Early‐onset colorectal cancer (EOCRC) is increasing globally and exhibits aggressive biology, yet reliable biomarker‐guided prognostic tools for postoperative patients remain scarce. We aimed to develop and validate an artificial intelligence (AI)–based prognostic model—EOCRCPred—that integrates serum carcinoembryonic antigen (CEA) and routine clinical variables for postoperative risk stratification in EOCRC. Patients and Methods We analyzed 7408 Stage I–III EOCRC patients from the SEER database (training/test) and 250 patients from two Chinese hospitals (external validation). After LASSO–Cox feature selection, six survival models (RSF, CoxPH, S‐SVM, XGBSE, Gradient Boosting Survival Analysis [GBSA], and DeepSurv) were constructed. Model performance was assessed via C‐index, time‐dependent AUC, Brier score, calibration, and decision curves. SHAP analysis identified key prognostic drivers, and an online calculator was deployed for clinical use.
Results
The GBSA model showed the most consistent discrimination, with integrated C‐indices of 0.774, 0.749, and 0.741 across training, test, and external validation cohorts, respectively, and mean AUCs of 0.812, 0.783, and 0.779. Calibration and decision curves confirmed its accuracy and net clinical benefit. SHAP analysis revealed serum CEA as the top prognostic driver, followed by chemotherapy, marital status, perineural invasion, and household income. The EOCRCPred risk stratification system effectively separated patients into low‐, intermediate‐, and high‐risk groups (all log‐rank p < 0.001). The web‐based tool ( https://eocrcpred.streamlit.app/ ) enables individualized 3‐ and 5‐year survival prediction.
Conclusions
EOCRCPred is an externally validated AI‐based prognostic model that integrates serum CEA with clinical parameters for postoperative survival prediction and risk stratification in EOCRC patients. The model showed consistent predictive performance across the training, test, and external validation cohorts and may have potential utility in personalized clinical management.
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
- Shanghai University of Traditional Chinese Medicine
Zitieren
APA
Wan, G., Wang, Q., Zhu, C., Wang, L., Zhu, Y., Li, M., Guo, S., Yu, H., & Yuan, L. (2026). EOCRCPred: An Artificial Intelligence–Based Prognostic Model Integrating Serum CEA and Clinical Factors for Early‐Onset Colorectal Cancer. International Journal of Clinical Practice, 2026(1). https://doi.org/10.1155/ijcp/9512983
Vancouver
Wan G, Wang Q, Zhu C, Wang L, Zhu Y, Li M, et al. EOCRCPred: An Artificial Intelligence–Based Prognostic Model Integrating Serum CEA and Clinical Factors for Early‐Onset Colorectal Cancer. International Journal of Clinical Practice. 2026;2026(1). doi:10.1155/ijcp/9512983
BibTeX
@article{Wan2026,
author = {Wan, Guangsheng and Wang, Qingjie and Zhu, Chunwu and Wang, Liyu and Zhu, Yongbao and Li, Meiying and Guo, Sheng and Yu, Hongjie and Yuan, Luyun},
title = {EOCRCPred: An Artificial Intelligence–Based Prognostic Model Integrating Serum CEA and Clinical Factors for Early‐Onset Colorectal Cancer},
journal = {International Journal of Clinical Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijcp/9512983}
}
EUVIMED